Primrose Bio raises Series C+ led by Signet Healthcare Partners

Primrose Bio Raises Series C+ Round

Primrose Bio, a San Diego, CA-based biotechnology company, has raised a Series C+ round led by Signet Healthcare Partners. The round also included participation from Agent Capital, LDV Partners, 1315 Capital and Ligand Pharmaceuticals.

What Primrose Bio Does

Primrose Bio develops and commercializes manufacturing technologies for biologics, mRNA and vaccine production. Its portfolio spans three core technology areas:

• Pfenex Expression Technology — a microbial protein-production platform used in six approved products, with yields up to 20x higher.
• Prima RNApols — RNA polymerase enzymes for scalable mRNA manufacturing.
• PeliCRM197 — a carrier protein used in conjugate vaccines.

Market Adoption

Several of the world's leading pharmaceutical companies use Primrose's technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen and Serum Institute of India.

Funding Details

• Round type: Series C+
• Lead investor: Signet Healthcare Partners
• Investors: Agent Capital, LDV Partners, Signet Healthcare Partners, 1315 Capital, Ligand Pharmaceuticals
• Announced: September 22, 2026

Why It Matters

Primrose Bio sits in the manufacturing technology layer of the biopharma value chain — the platforms and enzymes that enable biologics, mRNA and vaccine production at scale. Its Pfenex Expression Technology is already embedded in six approved products, and its customer list includes major pharmaceutical companies, giving the company validation across multiple marketed therapies.

The Series C+ structure, led by Signet Healthcare Partners with participation from a syndicate including Ligand Pharmaceuticals, suggests continued backing from both specialist healthcare investors and strategic industry participants. Ligand Pharmaceuticals' involvement is notable given its focus on royalty and technology platforms in the biopharma sector.

Technology Portfolio in Context

Primrose's three technology lines address distinct but related manufacturing needs:

• Protein production: Pfenex Expression Technology provides a microbial platform for producing proteins used in approved biologic products, with reported yield advantages of up to 20x.
• mRNA manufacturing: Prima RNApols supply RNA polymerase enzymes needed for scalable mRNA production — a capability relevant to vaccine and therapeutic developers.
• Conjugate vaccines: PeliCRM197 serves as a carrier protein in conjugate vaccine formulations.

Together, these technologies position Primrose as a supplier to multiple segments of the biopharma manufacturing market rather than a single-product company.

Acquisition Perspective

For acquirers in biopharma manufacturing, life sciences tools or vaccine production, Primrose Bio offers a portfolio of validated manufacturing technologies with existing adoption by major pharmaceutical companies. The presence of six approved products using its Pfenex platform provides a revenue-linked installed base, while the mRNA and conjugate vaccine technologies extend its reach into adjacent growth areas.

The Series C+ round, led by Signet Healthcare Partners and supported by a syndicate that includes Ligand Pharmaceuticals, reflects continued investor interest in the company's platform technologies. Strategic acquirers may see value in the customer relationships with companies such as Merck, Jazz Pharmaceuticals, Alvogen and Serum Institute of India, as well as the manufacturing IP across protein, mRNA and vaccine applications.

Summary

Primrose Bio has raised a Series C+ round led by Signet Healthcare Partners, with participation from Agent Capital, LDV Partners, 1315 Capital and Ligand Pharmaceuticals. The San Diego-based company develops manufacturing technologies for biologics, mRNA and vaccine production, including Pfenex Expression Technology, Prima RNApols and PeliCRM197. Its technologies are used in marketed products by companies including Merck, Jazz Pharmaceuticals, Alvogen and Serum Institute of India.